Frontline Combo Yields High Remission Rate in Hairy Cell Leukemia
(MedPage Today) -- Use of the BRAF inhibitor vemurafenib (Zelboraf) combined with the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) led to high rates of complete remission as frontline therapy for patients with hairy cell leukemia in a small... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 26, 2023 Category: Hematology Source Type: news
Venetoclax Shows Promise for R/R Hairy Cell Leukemia Venetoclax Shows Promise for R/R Hairy Cell Leukemia
Five of six patients with relapsed or refractory hairy cell leukemia experienced a response to venetoclax alone or in combination with rituximab.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 9, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market AstraZeneca Withdraws Drug for Hairy Cell Leukemia From US Market
The company is planning to remove its leukemia drug moxetumomab pasudotox-tdfk (Lumoxiti) from the US market, saying there has been ' very low clinical uptake ' of the product.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 13, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Study: Ibrutinib effective treatment for difficult to treat forms of hairy cell leukemia
(Ohio State University Wexner Medical Center) The oral targeted therapy drug ibrutinib is an effective treatment option for high-risk hairy cell leukemia, according to a new study conducted by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James). (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 21, 2021 Category: Cancer & Oncology Source Type: news
Cladribine With Concurrent or Delayed Rituximab in HCL Cladribine With Concurrent or Delayed Rituximab in HCL
Could the addition of rituximab to cladribine treatment help clear minimal residual disease in patients with hairy cell leukemia?Journal of Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 3, 2020 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news
FDA D.I.S.C.O.: FDA approval of moxetumomab pasudotox-tdfk for relapsed or refractory hairy cell leukemia
FDA medical oncologists discuss the Sept. 13, 2018, approval of moxetumomab pasudotox-tdfk for the treatment of patients with relapsed or refractory hairy cell leukemia (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 25, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Cladribine Plus Upfront Rituximab Shows Promise in Hairy Cell Leukemia
Researchers tested simultaneous vs delayed rituximab with cladribine in patients with hairy cell leukemia. (Source: CancerNetwork)
Source: CancerNetwork - June 10, 2019 Category: Cancer & Oncology Authors: Jim Kling Source Type: news
FDA Approves Novel Treatment for Hairy Cell Leukemia
Lumoxiti, a CD22 - directed cytotoxin, approved for adults who have had at least two prior therapies (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 15, 2018 Category: Cancer & Oncology Tags: Oncology, Pharmacy, Institutional, Source Type: news
FDA Approves Novel Treatment for Hairy Cell Leukemia
FRIDAY, Sept. 14, 2018 -- Lumoxiti (moxetumomab pasudotox-tdfk) injection has been approved to treat certain instances of relapsed or refractory hairy cell leukemia (HCL), the U.S. Food and Drug Administration said yesterday.
Lumoxiti, a... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 14, 2018 Category: Pharmaceuticals Source Type: news
Novel Treatment Approved for 'Hairy Cell' Leukemia
Title: Novel Treatment Approved for 'Hairy Cell' LeukemiaCategory: Health NewsCreated: 9/13/2018 12:00:00 AMLast Editorial Review: 9/14/2018 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - September 14, 2018 Category: Cancer & Oncology Source Type: news
FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia FDA Approves Lumoxiti, an Immunotoxin for Hairy Cell Leukemia
Moxetumomab pasudotox is a CD22-directed cytotoxin or immunotoxin and is a first-in-class type of treatment for patients with HCLFDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
FDA Approves Lumoxiti (moxetumomab pasudotox-tdfk) for Hairy Cell Leukemia
September 13, 2018 -- The U.S. Food and Drug Administration today approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who have... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - September 13, 2018 Category: Drugs & Pharmacology Source Type: news
Lumoxiti OK'd for Hairy Cell Leukemia
(MedPage Today) -- FDA approval marks first anti-CD22 drug for treating the rare disease (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 13, 2018 Category: Hematology Source Type: news
FDA approves AstraZeneca's drug for rare form of blood cancer
The U.S. Food and Drug Administration said on Thursday it approved AstraZeneca Plc's treatment for hairy cell leukemia, a slow-growing type of blood cancer. (Source: Reuters: Health)
Source: Reuters: Health - September 13, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
FDA approves new kind of treatment for hairy cell leukemia
FDA approves Lumoxiti (moxetumomab pasudotox-tdfk) for the treatment of adult patients with relapsed or refractory hairy cell leukemia (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 13, 2018 Category: American Health Source Type: news
